This report describes the services The Hilltop Institute provided to the Maryland Department of Health under their Master Agreement. The report covers fiscal year (FY) 2025 (July 1, 2024, through June 30, 2025). Hilltop’s interdisciplinary staff provided a wide range of services, including Medicaid program development and policy analysis; HealthChoice program support, evaluation, and financial analysis; long-term services and supports program development, policy analysis, and financial analytics; and data management and web-accessible database development.
This annual report, written for the UMBC community, provides an overview of key projects and staff accomplishments for FY 2025.
This report describes the services The Hilltop Institute provided to the Maryland Department of Health under their Master Agreement. The report covers fiscal year (FY) 2024 (July 1, 2023, through June 30, 2024). Hilltop’s interdisciplinary staff provided a wide range of services, including Medicaid program development and policy analysis; HealthChoice program support, evaluation, and financial analysis; long-term services and supports program development, policy analysis, and financial analytics; and data management and web-accessible database development.
This annual report, written for the UMBC community, provides an overview of key projects and staff accomplishments for FY 2024.
This report describes the services The Hilltop Institute provided to the Maryland Department of Health (MDH) under the Master Agreement between Hilltop and MDH. The report covers fiscal year (FY) 2023 (July 1, 2022, through June 30, 2023). Hilltop’s interdisciplinary staff provided a wide range of services, including Medicaid program development and policy analysis; HealthChoice program support, evaluation, and financial analysis; long-term services and supports program development, policy analysis, and financial analytics; and data management and web-accessible database development.
Treatment guidelines recommend regular urine drug testing (UDT) for persons initiating buprenorphine for opioid use disorder (OUD). However, little is known about UDT utilization. This study describes state variation in UDT utilization and examines demographic, health, and health care utilization factors associated with UDT in Medicaid.
Senior Policy Analyst Shamis Mohamoud was part of the Medicaid Outcomes Distributed Research Network (MODRN) team of authors of this article published in Drug and Alcohol Dependence.
Federal and state agencies granted temporary regulatory waivers to prevent disruptions in access to medication for opioid use disorder (MOUD) during the COVID-19 pandemic, including expanding access to telehealth for MOUD. To examine changes in MOUD receipt and initiation among Medicaid enrollees during the pandemic, this serial cross-sectional study included Medicaid enrollees aged 18 to 64 years in 10 states from May 2019 through December 2020.
Senior Policy Analyst Shamis Mohamoud co-authored this article published in JAMA Health Forum.
This report describes the services The Hilltop Institute provided to the Maryland Department of Health (the Department) under the Master Agreement between Hilltop and the Department. The report covers fiscal year (FY) 2022 (July 1, 2021, through June 30, 2022). Hilltop’s interdisciplinary staff provided a wide range of services, including Medicaid program development and policy analysis; HealthChoice program support, evaluation, and financial analysis; long-term services and supports program development, policy analysis, and financial analytics; and data management and web-accessible database development.
Limited information exists about testing for human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) among Medicaid enrollees after starting medication for opioid use disorder (MOUD), despite guidelines recommending such testing. The objectives of this cross-sectional study are to estimate testing prevalence and trends for HIV, HBV, and HCV among Medicaid enrollees initiating MOUD and examine enrollee characteristics associated with testing.
Senior Policy Analyst Shamis Mohamoud co-authored this article published in Clinical Infectious Diseases.
Using Medicaid data (2017 to 2018) from four states participating in a distributed research network, this retrospective cohort study documents the prevalence of specific types of co-occurring substance use disorder (SUD) among Medicaid enrollees with an opioid use disorder (OUD) diagnosis.
Senior Policy Analyst Shamis Mohamoud and Policy Analyst Rosa Perez were part of the Medicaid Outcomes Distributed Research Network (MODRN) team of authors of this article published in the Journal of Substance Abuse Treatment.